- South Korea
- /
- Medical Equipment
- /
- KOSDAQ:A340570
Is T&L Co., Ltd. (KOSDAQ:340570) Trading At A 33% Discount?
Key Insights
- The projected fair value for T&L is ₩76,738 based on 2 Stage Free Cash Flow to Equity
- T&L's ₩51,300 share price signals that it might be 33% undervalued
- T&L's peers are currently trading at a premium of 64% on average
Does the March share price for T&L Co., Ltd. (KOSDAQ:340570) reflect what it's really worth? Today, we will estimate the stock's intrinsic value by taking the expected future cash flows and discounting them to their present value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. Believe it or not, it's not too difficult to follow, as you'll see from our example!
Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.
Check out our latest analysis for T&L
The Calculation
We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.
A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we discount the value of these future cash flows to their estimated value in today's dollars:
10-year free cash flow (FCF) estimate
2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | |
Levered FCF (₩, Millions) | ₩20.0b | ₩24.0b | ₩27.0b | ₩29.5b | ₩31.7b | ₩33.5b | ₩35.2b | ₩36.6b | ₩37.9b | ₩39.1b |
Growth Rate Estimate Source | Analyst x1 | Analyst x1 | Est @ 12.44% | Est @ 9.43% | Est @ 7.32% | Est @ 5.85% | Est @ 4.82% | Est @ 4.10% | Est @ 3.59% | Est @ 3.24% |
Present Value (₩, Millions) Discounted @ 7.3% | ₩18.6k | ₩20.9k | ₩21.9k | ₩22.3k | ₩22.3k | ₩22.0k | ₩21.5k | ₩20.9k | ₩20.2k | ₩19.4k |
("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = ₩210b
The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (2.4%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 7.3%.
Terminal Value (TV)= FCF2033 × (1 + g) ÷ (r – g) = ₩39b× (1 + 2.4%) ÷ (7.3%– 2.4%) = ₩826b
Present Value of Terminal Value (PVTV)= TV / (1 + r)10= ₩826b÷ ( 1 + 7.3%)10= ₩409b
The total value is the sum of cash flows for the next ten years plus the discounted terminal value, which results in the Total Equity Value, which in this case is ₩619b. To get the intrinsic value per share, we divide this by the total number of shares outstanding. Compared to the current share price of ₩51k, the company appears quite undervalued at a 33% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.
The Assumptions
The calculation above is very dependent on two assumptions. The first is the discount rate and the other is the cash flows. If you don't agree with these result, have a go at the calculation yourself and play with the assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at T&L as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 7.3%, which is based on a levered beta of 0.913. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.
SWOT Analysis for T&L
- Earnings growth over the past year exceeded the industry.
- Currently debt free.
- Dividends are covered by earnings and cash flows.
- Dividend is low compared to the top 25% of dividend payers in the Medical Equipment market.
- Annual revenue is forecast to grow faster than the South Korean market.
- Trading below our estimate of fair value by more than 20%.
- No apparent threats visible for A340570.
Looking Ahead:
Valuation is only one side of the coin in terms of building your investment thesis, and it shouldn't be the only metric you look at when researching a company. DCF models are not the be-all and end-all of investment valuation. Rather it should be seen as a guide to "what assumptions need to be true for this stock to be under/overvalued?" For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. Why is the intrinsic value higher than the current share price? For T&L, we've compiled three pertinent aspects you should further research:
- Risks: Every company has them, and we've spotted 2 warning signs for T&L (of which 1 is potentially serious!) you should know about.
- Future Earnings: How does A340570's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
- Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!
PS. The Simply Wall St app conducts a discounted cash flow valuation for every stock on the KOSDAQ every day. If you want to find the calculation for other stocks just search here.
Valuation is complex, but we're here to simplify it.
Discover if T&L might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About KOSDAQ:A340570
T&L
Engages in the manufacture and sale of medical and polymer material products in South Korea.
Outstanding track record with flawless balance sheet.